July 16, 2025: Biocon share price, a leading player in the Pharmaceuticals sector and classified as a Largecap on the BSE, is showing impressive stock performance with its shares currently trading at ₹397. The stock experienced intra-day fluctuations between ₹393.25 and ₹405.85, edging close to its 52-week high of ₹404.6, highlighting renewed investor interest.
Over the last one day, Biocon Share Price recorded a gain of 1.72%, while the stock has surged 11.08% in the past month and an impressive 20.62% over the last three months. This upward momentum reflects strong market confidence in Biocon’s growth prospects and robust fundamentals.
From a technical standpoint, the daily pivot for Biocon Share Price stands at ₹397.65. The immediate resistance levels are ₹402.05 (R1), ₹410.25 (R2), and ₹414.65 (R3), while support levels are placed at ₹389.45 (S1), ₹385.05 (S2), and ₹376.85 (S3). These levels will be crucial in determining the stock’s short-term movement.
Moving averages provide additional insights into Biocon’s trend. The 5-day Simple Moving Average (SMA) is at ₹372.07, and the Exponential Moving Average (EMA) at ₹379.78, both signaling recent positive momentum. The 10-day SMA and EMA stand at ₹370.12 and ₹374.35 respectively, while the 50-day averages hover around ₹346-354, reflecting a steady upward trajectory.
Comparing Biocon’s performance within the sector reveals it as one of the stronger performers. The stock has recorded a 5.49% return over the past week and over 19% in the last three months, outperforming some competitors. Sun Pharmaceutical Industries, another major pharma stock, has gained 3.63% in the past week and 2.06% in the last three months, indicating relatively moderate growth.
Longer-term performance for Biocon shows mixed trends, with a modest 11.43% return over one year and a 3-year gain of 18.58%. However, the stock shows a slight decline over five years (-7.57%), which investors might weigh against recent strong performance and growth catalysts.
As Biocon navigates through these key technical levels and sector dynamics, investors are advised to monitor market developments and quarterly results closely to capitalize on potential opportunities in the pharmaceutical space.